CN103142521A - Glibenclamide tablet and preparation method thereof - Google Patents
Glibenclamide tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103142521A CN103142521A CN2013100921971A CN201310092197A CN103142521A CN 103142521 A CN103142521 A CN 103142521A CN 2013100921971 A CN2013100921971 A CN 2013100921971A CN 201310092197 A CN201310092197 A CN 201310092197A CN 103142521 A CN103142521 A CN 103142521A
- Authority
- CN
- China
- Prior art keywords
- glibenclamide
- mixed powder
- preparation
- blank granule
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004580 glibenclamide Drugs 0.000 title claims abstract description 87
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000011812 mixed powder Substances 0.000 claims abstract description 69
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims abstract description 7
- 235000010355 mannitol Nutrition 0.000 claims abstract description 7
- 239000004576 sand Substances 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 65
- 229960003943 hypromellose Drugs 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 238000012856 packing Methods 0.000 claims description 8
- 229920003023 plastic Polymers 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 8
- 229920001903 high density polyethylene Polymers 0.000 claims description 7
- 239000004700 high-density polyethylene Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000005434 MCC/mannitol excipient Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 10
- 239000002245 particle Substances 0.000 abstract 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 29
- 239000003814 drug Substances 0.000 description 13
- 238000007689 inspection Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 239000007962 solid dispersion Substances 0.000 description 5
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- FZOOOJPISNODNI-UHFFFAOYSA-N 5-chloro-2-methoxybenzamide Chemical compound COC1=CC=C(Cl)C=C1C(N)=O FZOOOJPISNODNI-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 benzenesulfonamido-Ethyl formate Chemical compound 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a glibenclamide tablet and a preparation method thereof. The preparation method comprises the following steps of: 1) uniformly mixing microcrystalline cellulose, mannitol and low substituted hydroxy propyl cellulose in a predetermined amount to obtain mixed power I; 2) adding an aqueous solution containing hydroxypropyl methylcellulose E50 in a predetermined amount to the mixed powder I to prepare fine sand hollow particles; 3) drying and screening the hollow particles; 4) mixing glibenclamide with 15-20% of hollow particles according to an equivalent progressively increase method to obtain mixed powder II; 5) uniformly mixing the mixed powder II and residual hollow particles to obtain mixed powder III; 6) uniformly mixing the mixed powder III with magnesium stearate to obtain mixed powder IV; and 7) tabletting the mixed powder IV according to predetermined weight of tablets to prepare the glibenclamide tablet. The glibenclamide tablet and the preparation method disclosed by the invention solve the problem that glibenclamide is sensitive to damp and hot and the problem of content uniformity, so that the dissolution rate of the glibenclamide tablet is improved.
Description
Technical field
The present invention relates to a kind of oral tablet and preparation method thereof, particularly a kind of Glibenclamide Tablets and preparation method thereof.
Background technology
Diabetes are to act on body by various virulence factors such as inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors, cause hypoinsulinism, insulin resistant etc. and the disease of the sugar that causes, protein, fat, metabolism disorder.Clinically take hyperglycemia as main feature, the performance such as polyuria, polydipsia, polyphagia can appear in model case, become thin.Diabetes are determine great of the slow sick summit of united state and need one of preferential main chronic disease of controlling, and China is diabetes big countries, and the type ii diabetes sickness rate is ascendant trend year by year, surpasses 9,000 ten thousand by the ill total number of persons of China in 2012.
Glibenclamide represents medicine as first of second filial generation sulfonylurea oral antidiabetic drug, in 1969 in European Initial Public Offering.Second filial generation medicine absorbs faster generally than the first generation, plasma protein binding rate is higher, acts on byer force, and toxicity is lower.Glibenclamide has been put into national essential drugs, mainly is applicable to unsatisfied light, the moderate type Ⅱdiabetes mellitus of alone diet control curative effect, and patient's beta Cell of islet has certain excreting insulin function, and without serious complication.
Glibenclamide Glibenclamide, its chemical name is: the N-[2-[4-[[[(cyclohexyl is amino) carbonyl] amino] sulfonyl] phenyl] ethyl]-2-methoxyl group-5-chlorobenzamide, molecular formula: C
23H
28ClN
3O
5The S molecular weight is 494.01.Its structural formula is as follows:
Glibenclamide is white crystalline powder, and almost odorless, tasteless; Be slightly soluble in methanol or ethanol, water insoluble or ether.Glibenclamide is stored more stable under normal operation, but more responsive to humidity ratio, and its hydrolytic process is similar to other sulfonylureas, and hydrolyzate is mainly that impurity I(has another name called impurity A): 4-[2(5-chloro-2-methoxy benzamide)-ethyl]-benzsulfamide.Therefore, its preparation such as tablet, capsule etc. are avoided high temperature, high humidity degraded at production process special requirement raw material.
The domestic literature report, Glibenclamide Tablets adopts direct powder compression, the mobility of the method to adjuvant, moisture etc. have extremely strict requirement; And research experiment as a comparison carries out raw material wet granulation together with adjuvant, and prompting slice, thin piece related substance changes in the phase obviously accelerating the effects.Following several drugs method for preparing tablet thereof is arranged at present usually:
" blank granule method " is mainly used in wet, thermally labile and wet granulation can first be used adjuvant by the less medicine of dosage, and be even with principal agent and mix lubricant after dry, screening, then carry out tabletting or packing.
Solid dispersions technique, being mainly used in insoluble drug increases stripping, improves bioavailability.Solid dispersion refers to that medicine with molecule, colloidal state, crystallite or amorphous state, is dispersed in the solid dispersion system of the medicine-carrier that forms in a kind of carrier mass.Wherein commonly used is water-solubility carrier, mainly comprises Polyethylene Glycol, polyvidone, poloxamer, saccharide, carbamide etc.In addition, some hydrophilic polymeies such as microcrystalline Cellulose, pregelatinized Starch also often are used as the carrier of surface of solids dispersion.
" equivalent progressively increase method " is mainly used in solving the homogeneity question of small dose drug.The general drug content that is used for is lower than in 5% situation.
Therefore, the necessary a kind of new Glibenclamide Tablets and preparation method thereof that provides can be according to the physicochemical property of glibenclamide self, integrated use " blank granule method ", " solid dispersion technology ", " equivalent progressively increase method " solves glibenclamide to damp and hot sensitive question; Improve the dissolution of insoluble drug glibenclamide, and solve small dose drug uniformity of dosage units problem.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of Glibenclamide Tablets and preparation method thereof, solves glibenclamide to damp and hot sensitive question; Improve the dissolution of glibenclamide, and solve medicament contg uniformity problem.
The present invention solves the problems of the technologies described above another technical scheme that adopts to be to provide a kind of Glibenclamide Tablets, comprise glibenclamide, filler, binding agent, disintegrating agent and lubricant, wherein said filler is microcrystalline Cellulose and mannitol, described disintegrating agent is low replacement-hydroxypropyl cellulose, described binding agent is hypromellose E50, described lubricant is magnesium stearate, and each compositions in weight percentage is:
Glibenclamide 3%～5%;
Microcrystalline Cellulose 70%～80%;
Mannitol 10%～18.7%;
L-hydroxypropyl cellulose 2.5%～6.5%;
Hypromellose E50 0.7%～2%
Magnesium stearate 0.4%～1.2%.
The present invention solves the problems of the technologies described above the preparation method that another technical scheme that adopts is to provide a kind of Glibenclamide Tablets, comprises the steps: 1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of scheduled volume, mixing gets mixed powder I; 2) add scheduled volume to contain the aqueous solution of hypromellose E50, to mixed powder I, make the blank granule of fine sand shape; 3) dry and screen described blank granule; 4) glibenclamide is mixed by the equivalent method of progressively increasing with the blank granule of 15%-20%, get mixed powder II; 5) with mixed powder II and remaining blank granule mixing, get mixed powder III; 6) with mixed powder III and magnesium stearate mixing, get mixed powder IV; 7) heavy according to pre-stator, mixed powder IV is carried out tabletting, make Glibenclamide Tablets.
Further, in described step 1), mixed powder I is added the efficient wet comminutor, high-speed stirred 3-7 minute.
Further, the aqueous solution that contains hypromellose E50 described step 2) is that 2 ﹕ 98 are formulated by hypromellose E50 and water by weight proportion.
Further, in described step 3), during dry described blank granule, described blank granule is moved in baking oven, 70-75 ℃ of aeration-drying 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%.
Further, in described step 3), during the described blank granule of screening, described blank granule is crossed 20～40 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves.
Further, in described step 4), glibenclamide is progressively increased by 4-6 equivalent with the blank granule of 15%-20% mix.
Further, in described step 5), mixed powder II was mixed in mixer 20-30 minute with remaining blank granule, in described step 6), described mixed powder III mixed in mixer with magnesium stearate 5-15 minute.
Further, adopting 5.5mm shallow concave punch tool and hardness during tabletting in described step 7) is that 2.5-4kgf carries out tabletting.
Further, the Glibenclamide Tablets that makes in described step 7) adopts high-density polyethylene plastics bottle packing.
The present invention contrasts prior art following beneficial effect: Glibenclamide Tablets provided by the invention and preparation method thereof, can be according to the physicochemical property of glibenclamide self, integrated use " blank granule method ", hydrophilic microcrystalline cellulose is the solid dispersion technology of main carriers, " equivalent progressively increase method ", has following advantage: 1. owing to adopting " blank granule method ", avoided the sensitivity of glibenclamide to high temperature, high humidity.Therefore, adopt the Glibenclamide Tablets of the present invention's preparation, related substance and content without significantly changing, thereby have improved stability and the quality controllability of product before the deadline; 2. adopt the dispersion technology take hydrophilic microcrystalline Cellulose as main carriers, thereby improved the dissolution of glibenclamide; 3. adopted " equivalent progressively increase method ", solved the uniformity of dosage units problem of small dose drug; 4. due to the common adjuvant that has adopted non-direct compression, reduced cost of supplementary product.
Description of drawings
Fig. 1 is the process chart of embodiment of the present invention Glibenclamide Tablets preparation.
The specific embodiment
The invention will be further described below in conjunction with drawings and Examples.
Glibenclamide Tablets provided by the invention and preparation method thereof, preparation technology's the below to Glibenclamide Tablets is elaborated as an example of specification 2.5mg example.
Embodiment 1
Preparation method and step:
1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of above-mentioned weight, mixing gets mixed powder I; Mixed powder I is added the efficient wet comminutor, high-speed stirred 3 minutes; 2) add 175g2% hypromellose E50 aqueous solution, to mixed powder I, make the blank granule of fine sand shape; 2% hypromellose E50 aqueous solution is that 2 ﹕ 98 are formulated by hypromellose E50 and water by weight proportion; 3) described blank granule is moved in baking oven, 70 ℃ of aeration-dryings 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%; After drying, described blank granule is crossed 20 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves; 4) with the glibenclamide of 25g by the progressively increase abundant mix homogeneously of blank granule of method and 15% of equivalent, get mixed powder II; The present embodiment moderate method of progressively increasing is first got 1 part of glibenclamide, 1 part of blank granule, and mix homogeneously dilutes half with the content of glibenclamide; Get 2 parts of blank granules, with the mixed powder mix homogeneously of front, the content of glibenclamide dilutes half more again; So repeatedly dilute, mix, after 4 times, can achieve the goal.5) mixed powder II was mixed in mixer 20 minutes with remaining blank granule, get mixed powder III; 6) mixed powder III was mixed in mixer 5 minutes with the 2g magnesium stearate, get mixed powder IV; 7) 50mg/ sheet heavy according to pre-stator, carry out tabletting to mixed powder IV, and adopting 5.5mm shallow concave punch tool and hardness during tabletting is 2.5-4kgf, makes 10000 Glibenclamide Tablets; At last, the Glibenclamide Tablets that makes is carried out quality inspection, the employing high-density polyethylene plastics bottle packing that quality inspection is qualified.
Embodiment 2
Preparation method and step:
1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of above-mentioned weight, mixing gets mixed powder I; Mixed powder I is added the efficient wet comminutor, high-speed stirred 5 minutes; 2) add 750g2% hypromellose E50 aqueous solution, to mixed powder I, make the blank granule of fine sand shape; 2% hypromellose E50 aqueous solution is that 2 ﹕ 98 are formulated by hypromellose E50 and water by weight proportion; 3) described blank granule is moved in baking oven, 73 ℃ of aeration-dryings 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%; After drying, described blank granule is crossed 30 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves; 4) with the glibenclamide of 25g by the progressively increase abundant mix homogeneously of blank granule of method and 18% of equivalent, get mixed powder II; The present embodiment moderate method of progressively increasing is first got 1 part of glibenclamide, 1 part of blank granule, and mix homogeneously dilutes half with the content of glibenclamide; Get 2 parts of blank granules, with the mixed powder mix homogeneously of front, the content of glibenclamide dilutes half more again; So repeatedly dilute, mix, after 5 times, can achieve the goal.5) mixed powder II was mixed in mixer 25 minutes with remaining blank granule, get mixed powder III; 6) mixed powder III was mixed in mixer 10 minutes with the 9.6g magnesium stearate, get mixed powder IV; 7) 83.4mg/ sheet heavy according to pre-stator, carry out tabletting to mixed powder IV, and adopting 5.5mm shallow concave punch tool and hardness during tabletting is 2.5-4kgf, makes 10000 Glibenclamide Tablets; At last, the Glibenclamide Tablets that makes is carried out quality inspection, the employing high-density polyethylene plastics bottle packing that quality inspection is qualified.
Embodiment 3
Preparation method and step:
1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of above-mentioned weight, mixing gets mixed powder I; Mixed powder I is added the efficient wet comminutor, high-speed stirred 7 minutes; 2) add 700g2% hypromellose E50 aqueous solution, to mixed powder I, make the blank granule of fine sand shape; 2% hypromellose E50 aqueous solution is that 2 ﹕ 98 are formulated by hypromellose E50 and water by weight proportion; 3) described blank granule is moved in baking oven, 75 ℃ of aeration-dryings 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%; After drying, described blank granule is crossed 40 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves; 4) with the glibenclamide of 25g by the progressively increase abundant mix homogeneously of blank granule of method and 20% of equivalent, get mixed powder II; The present embodiment moderate method of progressively increasing is first got 1 part of glibenclamide, 1 part of blank granule, and mix homogeneously dilutes half with the content of glibenclamide; Get 2 parts of blank granules, with the mixed powder mix homogeneously of front, the content of glibenclamide dilutes half more again; So repeatedly dilute, mix, after 5 times, can achieve the goal.5) mixed powder II was mixed in mixer 30 minutes with remaining blank granule, get mixed powder III; 6) mixed powder III was mixed in mixer 15 minutes with the 6g magnesium stearate, get mixed powder IV; 7) 70mg/ sheet heavy according to pre-stator, carry out tabletting to mixed powder IV, and adopting 5.5mm shallow concave punch tool and hardness during tabletting is 2.5-4kgf, makes 10000 Glibenclamide Tablets; At last, the Glibenclamide Tablets that makes is carried out quality inspection, the employing high-density polyethylene plastics bottle packing that quality inspection is qualified.
Embodiment 4
Preparation method and step:
1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of above-mentioned weight, mixing gets mixed powder I; Mixed powder I is added the efficient wet comminutor, high-speed stirred 5 minutes; 2) add 21.5kg2% hypromellose E50 solution, to mixed powder I, make the blank granule of fine sand shape; 2% hypromellose E50 aqueous solution is that 2 ﹕ 98 are formulated by hypromellose E50 and water by weight proportion; 3) described blank granule is moved in baking oven, 73 ℃ of aeration-dryings 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%; After drying, described blank granule is crossed 30 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves; 4) with the glibenclamide of 1.25kg by the progressively increase abundant mix homogeneously of blank granule of method and 20% of equivalent, get mixed powder II; The present embodiment moderate method of progressively increasing is first got 1 part of glibenclamide, 1 part of blank granule, and mix homogeneously dilutes half with the content of glibenclamide; Get 2 parts of blank granules, with the mixed powder mix homogeneously of front, the content of glibenclamide dilutes half more again; So repeatedly dilute, mix, after 6 times, can achieve the goal.5) mixed powder II was mixed in mixer 25 minutes with remaining blank granule, get mixed powder III; 6) mixed powder III was mixed in mixer 10 minutes with the 0.25Kg magnesium stearate, get mixed powder IV; 7) 62.5mg/ sheet heavy according to pre-stator, carry out tabletting to mixed powder IV, and adopting 5.5mm shallow concave punch tool and hardness during tabletting is 2.5-4kgf, makes 500000 Glibenclamide Tablets; At last, the Glibenclamide Tablets that makes is carried out quality inspection, the employing high-density polyethylene plastics bottle packing that quality inspection is qualified.
The present invention investigates respectively dissolution and the uniformity of dosage units (assay method is according to 2010 editions two ones 809 pages of Chinese Pharmacopoeias) of embodiment 1, embodiment 2, embodiment 3, embodiment 4
Each embodiment dissolution of table 1, uniformity of dosage units
The data of each embodiment dissolution of table 1, uniformity of dosage units show: the glibenclamide flake products of the present invention's preparation conforms to quality requirements.During screening, all can reach the uniformity of dosage units requirement by 20 orders, 30 orders and 40 mesh sieves, take into full account the tabletting factor, cross the requirement that 30 mesh sieves are more suitable for suitability for industrialized production.
The present invention carries out factors influencing with embodiment 1, investigate respectively 60 ℃ of high temperature, high humidity (25 ℃, relative humidity 92.5%) and illumination 4500 ± 500lx condition content of lower 0 day, 5 days, 10 days and the situation of change of related substance: (assay method is according to 2010 editions two ones 809 pages of Chinese Pharmacopoeias)
Table 2 embodiment 1 factors influencing information slip
Influence factor's experiment shows: the content of Glibenclamide Tablets provided by the invention, related substance are subjected to the impact of high temperature, illumination less, and high humidity has certain impact.
The present invention with embodiment 1, embodiment 2, embodiment 3 the totally three batches of test samples pack with the high-density polyethylene plastics bottles, put into 40 ± 2 ℃, accelerated 6 months sampling and measuring in the calorstat of relative humidity 75% ± 5%; Separately with embodiment 1, embodiment 2, embodiment 3 totally three batches of test sample plastic bottle packings, 25 ± 2 ℃ of temperature, carry out 6 months long-term experiments in the calorstat of relative humidity 60% ± 10%, investigate the indices such as content, related substance, dissolution.(assay method is according to 2010 editions two ones 809 pages of Chinese Pharmacopoeias)
[0061] table 3 embodiment 1, enforcement 2, embodiment 3 accelerate and the long-term investigation information slips
Annotate: impurity I:4-[2-(5-chloro-2-methoxy benzamide)-ethyl]-benzsulfamide;
Impurity II:4-[2-(5-chloro-2-methoxy benzamide)-ethyl]-the benzenesulfonamido-Ethyl formate.
The stability test result shows, the Glibenclamide Tablets product content that the embodiment of the present invention obtains is stable, and related substance does not obviously increase, and the dissolution superior performance meets the prescription of tablet.
In sum, the present invention adopts " blank granule method ", has increased the granularity of common adjuvant by granulation, has improved the mobility of adjuvant, is conducive to tabletting; To be scattered in less than 100 purpose glibenclamide raw materials, take hydrophilic microcrystalline cellulose as main carriers in the dispersion of (account for whole dispersion 70%～80%), the sheet that is pressed into, the stripping behavior that can greatly improve glibenclamide; Adopt " equivalent progressively increase method " to solve the homogeneity question of medicament contg, therefore, Glibenclamide Tablets provided by the invention and preparation method thereof has solved glibenclamide to damp and hot sensitivity and uniformity of dosage units problem, has improved the dissolution of Glibenclamide Tablets.
Although the present invention discloses as above with preferred embodiment; so it is not to limit the present invention, any those skilled in the art, without departing from the spirit and scope of the present invention; when can do a little modification and perfect, so protection scope of the present invention is when with being as the criterion that claims were defined.
Claims (10)
1. Glibenclamide Tablets, comprise glibenclamide, filler, binding agent, disintegrating agent and lubricant, it is characterized in that described filler is microcrystalline Cellulose and mannitol, described disintegrating agent is low replacement-hydroxypropyl cellulose, described binding agent is hypromellose E50, described lubricant is magnesium stearate, and each compositions in weight percentage is:
Glibenclamide 3%～5%;
Microcrystalline Cellulose 70%～80%;
Mannitol 10%～18.7%;
L-hydroxypropyl cellulose 2.5%～6.5%;
Hypromellose E50 0.7%～2%
Magnesium stearate 0.4%～1.2%.
2. the preparation method of a Glibenclamide Tablets as claimed in claim 1, comprise the steps:
1) with microcrystalline Cellulose, mannitol and the low-substituted hydroxypropyl cellulose of scheduled volume, mixing gets mixed powder I;
2) add scheduled volume to contain the aqueous solution of hypromellose E50, to mixed powder I, make the blank granule of fine sand shape;
3) dry and screen described blank granule;
4) glibenclamide is mixed by the equivalent method of progressively increasing with the blank granule of 15%-20%, get mixed powder II;
5) with mixed powder II and remaining blank granule mixing, get mixed powder III;
6) with mixed powder III and magnesium stearate mixing, get mixed powder IV;
7) heavy according to pre-stator, mixed powder IV is carried out tabletting, make Glibenclamide Tablets.
3. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, in described step 1), mixed powder I added the efficient wet comminutor, high-speed stirred 3-7 minute.
4. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, described step 2) in contain hypromellose E50 aqueous solution be that 2 ﹕ 98 are formulated by weight proportion by hypromellose E50 and water.
5. the preparation method of Glibenclamide Tablets as claimed in claim 2, it is characterized in that, in described step 3), during dry described blank granule, described blank granule is moved in baking oven, 70～75 ℃ of aeration-dryings 2 hours, make the moisture in blank granule be controlled at 2.2-3.0%.
6. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, in described step 3), during the described blank granule of screening, described blank granule crossed 20～40 mesh sieves, and be no less than 80% by the blank granule of 50 mesh sieves.
7. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, in described step 4), glibenclamide progressively increased by 4-6 equivalent with the blank granule of 15%-20% mix.
8. the preparation method of Glibenclamide Tablets as claimed in claim 2, it is characterized in that, in described step 5), mixed powder II was mixed in mixer 20-30 minute with remaining blank granule, in described step 6), described mixed powder III mixed in mixer with magnesium stearate 5-15 minute.
9. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, adopting 5.5mm shallow concave punch tool and hardness during tabletting in described step 7) is that 2.5-4kgf carries out tabletting.
10. the preparation method of Glibenclamide Tablets as claimed in claim 2, is characterized in that, the Glibenclamide Tablets that makes in described step 7) adopts high-density polyethylene plastics bottle packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310092197.1A CN103142521B (en) | 2013-03-21 | 2013-03-21 | Glibenclamide tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310092197.1A CN103142521B (en) | 2013-03-21 | 2013-03-21 | Glibenclamide tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142521A true CN103142521A (en) | 2013-06-12 |
| CN103142521B CN103142521B (en) | 2014-06-25 |
Family
ID=48541037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310092197.1A Expired - Fee Related CN103142521B (en) | 2013-03-21 | 2013-03-21 | Glibenclamide tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142521B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705482A (en) * | 2014-01-15 | 2014-04-09 | 宜昌长江药业有限公司 | Preparation method of tiopronin tablets |
| EP3744314A1 (en) * | 2019-05-31 | 2020-12-02 | Shin-Etsu Chemical Co., Ltd. | Method for producing tablet |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1395560A (en) * | 2000-01-14 | 2003-02-05 | 布里斯托尔-迈尔斯斯奎布公司 | Glyburide composition |
| CN1660057A (en) * | 2004-12-29 | 2005-08-31 | 王召 | Glibenclamide solid dispersion, oral composition and preparation method thereof |
| CN1839801A (en) * | 2005-03-31 | 2006-10-04 | 北京德众万全医药科技有限公司 | Insoluble pharmaceutical slow release preparation |
| US8303868B2 (en) * | 2009-01-26 | 2012-11-06 | Shin-Etsu Chemical Co., Ltd. | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose |
-
2013
- 2013-03-21 CN CN201310092197.1A patent/CN103142521B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1395560A (en) * | 2000-01-14 | 2003-02-05 | 布里斯托尔-迈尔斯斯奎布公司 | Glyburide composition |
| CN1660057A (en) * | 2004-12-29 | 2005-08-31 | 王召 | Glibenclamide solid dispersion, oral composition and preparation method thereof |
| CN1839801A (en) * | 2005-03-31 | 2006-10-04 | 北京德众万全医药科技有限公司 | Insoluble pharmaceutical slow release preparation |
| US8303868B2 (en) * | 2009-01-26 | 2012-11-06 | Shin-Etsu Chemical Co., Ltd. | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose |
Non-Patent Citations (1)
| Title |
|---|
| P.MURA,ET AL: "optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705482A (en) * | 2014-01-15 | 2014-04-09 | 宜昌长江药业有限公司 | Preparation method of tiopronin tablets |
| EP3744314A1 (en) * | 2019-05-31 | 2020-12-02 | Shin-Etsu Chemical Co., Ltd. | Method for producing tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142521B (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301084B (en) | Berberine hydrochloride tablet and preparation method thereof | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| CN102552258B (en) | Pharmaceutical composition containing repaglinide and preparation method of same | |
| CN104586834A (en) | Pharmaceutical composition of empagliflozin and metformin and preparation method thereof | |
| CN103479592A (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| CN103142521B (en) | Glibenclamide tablet and preparation method thereof | |
| CN110833529A (en) | Terbinafine hydrochloride tablet and preparation method thereof | |
| CN102988993A (en) | Screening and composition of main auxiliary materials of compound acetaminophen tablet, and preparation method of compound acetaminophen tablet | |
| CN105233300B (en) | A kind of stable vildagliptin composition and preparation method thereof | |
| CN111773194B (en) | Canagliflozin tablet and preparation method thereof | |
| CN105213335B (en) | Glipizide tablet as well as preparation method and application thereof | |
| CN102488711A (en) | Method for preparing compound paracetamol and amantadine hydrochloride tablet | |
| CN102755301B (en) | Glimepiride tablet and preparation method thereof | |
| CN101167731A (en) | Dispersible tablet containing metformin and glibenclamide and preparation method thereof | |
| CN103251593B (en) | Repaglinide/metformin composition | |
| CN109481412A (en) | A kind of II crystal linezolid piece and its preparation process | |
| CN102302466A (en) | Capecitabine medicinal composition capable of direct powder tableting, and application thereof | |
| CN111000806A (en) | Ibrutinib tablet composition | |
| CN102379855A (en) | Glimepiride dispersible tablet and preparation method thereof | |
| CN103251569A (en) | Capecitabine tablet composition and preparation method thereof | |
| CN103251594A (en) | Repaglinide/metformin combo tablet | |
| CN110585155A (en) | Gliclazide tablet (II) and preparation method thereof | |
| CN102240270A (en) | Blonanserin tablet and preparation method thereof | |
| CN102988372A (en) | Screening and composition of main auxiliary materials of compound aspirin tablet, and preparation method of compound aspirin sheet | |
| CN112156077B (en) | N-acetylglucosamine tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 Termination date: 20190321 |